Amgen Gets Clearance On Product Collaboration

Thousand Oaks-based biotech giant Amgen said late Monday that it has received clearance on a product collaboration with Servier. According to Amgen, it received an early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976, in connection with a deal announced in July to license the rights to a heart failure drug from Servier. Amgen said it had obtained commercial rights in the U.S. to Servier's Procoralan(ivabradine) compound, for treating chronic heart failure and stable angina. The deal also includes an option to develop and commercialize an investigational molecule from Servier, S38844, being aimed at heart failure treatment.